Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ATOS NASDAQ:CYPH NASDAQ:RANI NASDAQ:SPRO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATOSAtossa Genetics$2.40-3.6%$3.38$1.70▼$19.35$20.66M1.25139,463 shs105,839 shsCYPHCypherpunk Technologies$0.74+3.1%$0.85$0.23▼$3.70$78.68M0.073.53 million shs1.43 million shsRANIRani Therapeutics$0.69+0.7%$0.83$0.42▼$3.87$85.60M0.781.01 million shs544,360 shsSPROSpero Therapeutics$1.38-4.2%$2.42$1.37▼$3.08$79.90M1.49768,786 shs2.18 million shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATOSAtossa Genetics0.00%+3.75%+23.88%-56.85%-80.28%CYPHCypherpunk Technologies+1.24%+2.60%-3.02%-12.12%+108.40%RANIRani Therapeutics-1.58%+8.49%-12.28%-27.59%+65.13%SPROSpero Therapeutics-8.86%-33.94%-36.84%-48.57%-39.24%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATOSAtossa Genetics$2.40-3.6%$3.38$1.70▼$19.35$20.66M1.25139,463 shs105,839 shsCYPHCypherpunk Technologies$0.74+3.1%$0.85$0.23▼$3.70$78.68M0.073.53 million shs1.43 million shsRANIRani Therapeutics$0.69+0.7%$0.83$0.42▼$3.87$85.60M0.781.01 million shs544,360 shsSPROSpero Therapeutics$1.38-4.2%$2.42$1.37▼$3.08$79.90M1.49768,786 shs2.18 million shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATOSAtossa Genetics0.00%+3.75%+23.88%-56.85%-80.28%CYPHCypherpunk Technologies+1.24%+2.60%-3.02%-12.12%+108.40%RANIRani Therapeutics-1.58%+8.49%-12.28%-27.59%+65.13%SPROSpero Therapeutics-8.86%-33.94%-36.84%-48.57%-39.24%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATOSAtossa Genetics 2.20Hold$20.33747.22% UpsideCYPHCypherpunk Technologies 2.50Moderate Buy$0.9021.79% UpsideRANIRani Therapeutics 2.60Moderate Buy$8.751,166.28% UpsideSPROSpero Therapeutics 1.50ReduceN/AN/ACurrent Analyst Ratings BreakdownLatest ATOS, RANI, CYPH, and SPRO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/17/2026RANIRani Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)7/17/2026SPROSpero Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)7/10/2026CYPHCypherpunk Technologies Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)7/7/2026ATOSAtossa Genetics Rodman & RenshawSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$12.007/3/2026CYPHCypherpunk Technologies Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy7/1/2026CYPHCypherpunk Technologies Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$0.907/1/2026CYPHCypherpunk Technologies Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$0.906/25/2026CYPHCypherpunk Technologies Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)6/24/2026RANIRani Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)6/11/2026ATOSAtossa Genetics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/22/2026ATOSAtossa Genetics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)(Data available from 7/21/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATOSAtossa GeneticsN/AN/AN/AN/A$4.57 per shareN/ACYPHCypherpunk TechnologiesN/AN/AN/AN/A$1.83 per shareN/ARANIRani Therapeutics$1.63M52.52N/AN/A$0.34 per share2.03SPROSpero Therapeutics$66.80M1.20$0.13 per share10.39$1.05 per share1.31Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATOSAtossa Genetics-$34.77M-$3.21N/AN/AN/AN/A-84.91%-72.36%8/11/2026 (Estimated)CYPHCypherpunk Technologies$4.82M-$0.02N/AN/AN/AN/A-48.33%-42.21%N/ARANIRani Therapeutics-$29.67M-$0.41N/AN/AN/AN/A-206.46%-83.95%8/6/2026 (Estimated)SPROSpero Therapeutics$8.57M$0.245.75N/AN/A24.90%35.58%24.95%8/11/2026 (Estimated)Latest ATOS, RANI, CYPH, and SPRO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2026Q2 2026ATOSAtossa Genetics-$1.04N/AN/AN/AN/AN/A8/11/2026Q2 2026SPROSpero Therapeutics-$0.17N/AN/AN/A$0.28 millionN/A8/6/2026Q2 2026RANIRani Therapeutics-$0.05N/AN/AN/A$0.93 millionN/A5/15/2026Q1 2026RANIRani Therapeutics-$0.06-$0.04+$0.02-$0.04$1.13 million$1.71 million5/14/2026Q1 2026CYPHCypherpunk Technologies-$0.0406-$0.46-$0.4194-$0.46N/AN/A5/13/2026Q1 2026SPROSpero Therapeutics-$0.18-$0.13+$0.05-$0.13$0.26 million$0.26 million5/8/2026Q1 2026ATOSAtossa Genetics-$0.99-$1.11-$0.12-$1.11N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthATOSAtossa GeneticsN/AN/AN/AN/AN/ACYPHCypherpunk TechnologiesN/AN/AN/AN/AN/ARANIRani TherapeuticsN/AN/AN/AN/AN/ASPROSpero TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATOSAtossa GeneticsN/A4.924.92CYPHCypherpunk TechnologiesN/A27.2827.28RANIRani TherapeuticsN/A3.403.40SPROSpero TherapeuticsN/A10.5010.50Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATOSAtossa Genetics12.74%CYPHCypherpunk Technologies30.46%RANIRani Therapeutics30.19%SPROSpero Therapeutics25.60%Insider OwnershipCompanyInsider OwnershipATOSAtossa Genetics9.80%CYPHCypherpunk Technologies3.50%RANIRani Therapeutics26.73%SPROSpero Therapeutics2.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATOSAtossa Genetics88.61 million7.77 millionOptionableCYPHCypherpunk Technologies40106.46 million102.74 millionOptionableRANIRani Therapeutics110123.88 million90.77 millionOptionableSPROSpero Therapeutics15057.90 million56.22 millionOptionableATOS, RANI, CYPH, and SPRO HeadlinesRecent News About These CompaniesSpero Therapeutics (NASDAQ:SPRO) Stock Crosses Below 200-Day Moving Average - Here's WhyJuly 17, 2026 | marketbeat.comSpero Therapeutics inks major CD40L and royalty dealsJuly 16, 2026 | theglobeandmail.comSpero Therapeutics: 'Buy' On Utebzi Royalty Deal For Funding And SP001 In-LicensingJuly 14, 2026 | seekingalpha.comSpero licenses Innovent's experimental immune disease drug for up to $1.1 billionJuly 14, 2026 | reuters.comSpero gets ex-China rights to Innovent’s antibody therapy for up to $1.1BJuly 14, 2026 | msn.comSpero Therapeutics Lands $105 Million Royalty Financing to Advance SP001 Development (SPRO)July 14, 2026 | finance.yahoo.comSpero Therapeutics Secures $105 Million Royalty Financing to Advance SP001 and Extend Cash Runway Through Second Half of 2029July 14, 2026 | quiverquant.comQSpero Therapeutics Announces $105 Million Non-Recourse Non-Dilutive Financing Backed by a Portion of Utebzi Milestones & RoyaltiesJuly 14, 2026 | globenewswire.comSpero Therapeutics and Innovent Biologics Announce Exclusive License for SP001 (IBI355), a Phase 2-Ready Third-Generation Anti-CD40L AntibodyJuly 14, 2026 | globenewswire.comInnovent Biologics and Spero Therapeutics Announce Exclusive License for IBI355 (SP001), a Phase 2-Ready Third-Generation Anti-CD40L AntibodyJuly 14, 2026 | prnewswire.comSpero Therapeutics (NASDAQ:SPRO) Stock Crosses Below 200 Day Moving Average - What's Next?July 9, 2026 | marketbeat.comAvacta Appoints Healthcare Executive Patrick Vink as Deputy Chairman of the Board of DirectorsJuly 8, 2026 | globenewswire.comSPRO Share News TodayJune 30, 2026 | uk.investing.comBiggest stock movers Thursday: INTC, KR, ACN, and moreJune 18, 2026 | seekingalpha.comSpero shares jump after FDA clears first oral carbapenem antibiotic for US market (SPRO)June 18, 2026 | msn.comGSK's Utebzi Wins FDA Nod for Complicated Urinary Tract InfectionsJune 18, 2026 | zacks.comSpero Therapeutics, Inc.: Utebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs)June 18, 2026 | finanznachrichten.deFDA approves first oral carbapenem therapy for cUTIsJune 17, 2026 | thepharmaletter.comTUtebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs)June 17, 2026 | globenewswire.comSpero Therapeutics: Approval Upside, Commercial Friction (Initiating Hold)June 10, 2026 | seekingalpha.comSpero Therapeutics Announces First Quarter 2026 Operating Results and Provides Business UpdateMay 13, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesEnergy Fuels Just Made a Bold Bet on Rare Earth MagnetsBy Jeffrey Neal Johnson | June 25, 2026Uncle Sam Plugs In: Nuclear Energy’s Cash Flow Moment Is Finally HereBy Jeffrey Neal Johnson | June 26, 20263 ETFs Pairing Market-Beating Returns With High Dividend YieldsBy Nathan Reiff | June 27, 2026Drone Stocks Are Down, But Defense Backlogs Tell a Different StoryBy Thomas Hughes | July 8, 2026Why These 3 Nuclear ETFs Are Getting a Fresh Look as AI Power Demand RisesBy Nathan Reiff | July 19, 2026ATOS, RANI, CYPH, and SPRO Company DescriptionsAtossa Genetics NASDAQ:ATOS$2.40 -0.09 (-3.61%) Closing price 04:00 PM EasternExtended Trading$2.40 +0.00 (+0.21%) As of 04:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.Cypherpunk Technologies NASDAQ:CYPH$0.74 +0.02 (+3.08%) As of 04:00 PM EasternLeap Therapeutics, Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501. Leap Therapeutics, Inc. has an option and license agreement with NovaRock, Adimab, and BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.Rani Therapeutics NASDAQ:RANI$0.69 +0.00 (+0.68%) Closing price 04:00 PM EasternExtended Trading$0.69 0.00 (-0.14%) As of 05:03 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.Spero Therapeutics NASDAQ:SPRO$1.38 -0.06 (-4.17%) Closing price 04:00 PM EasternExtended Trading$1.38 +0.00 (+0.07%) As of 05:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; and Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. Spero Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 3M's Redemption Arc: Can Q2 Earnings Change the Narrative? Alphabet Is Planning a New AI Chip. Here's Why It Matters Ahead of Earnings 3 Photonics Companies Making Quantum Tech Possible Confidence Is Back, But Earnings Show the Consumer Is Being Picky Industrial and Utility Giants Boost Dividends as Data Center Tailwinds Build IREN’s $2.8 Billion AI Contract Haul Changes the Stock’s Story AeroVironment’s Stock Is Down, But Drone Demand Is Taking Off 2 ETFs to Access the World's Best-Performing Stock Markets In 2026 Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
